Is Aurinia Pharmaceuticals Stock a Buy?
Canadian biopharma Aurinia Pharmaceuticals (NASDAQ: AUPH) is undergoing a transformation. The company is embarking on a rare opportunity to deliver the first U.S. Food and Drug Administration (FDA) approved therapy for the treatment of lupus nephritis (LN), a serious inflammation of the kidneys caused by an autoimmune disorder called systemic lupus erythematosus (SLE).
On the heels of receiving positive clinical data from its phase 3 Aurora study in December, the company completed its submission for a New Drug Application (NDA) to the FDA for this promising treatment known as voclosporin. Aurinia expects this submission to be expedited via priority review, which will support its plans to launch in early 2021. With the biopharma company currently valued at nearly $1.7 billion and on the brink of a potential drug approval, do investors have a blockbuster opportunity on their hands?
Let's take a closer look.
Source Fool.com